Skip to main navigation
  • LogicBio Therapeutics, Inc.

Investors

  • About
  • Platforms
    • GeneRide
    • Overview
    • Partnering
    • Publications
    • sAAVy
  • Pipeline
  • Patients & Families
    • About MMA
    • Patient Stories
    • Community Resources
    • Clinical Trials
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • Financial informations
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • IR Search
  • Careers
  • Contact

Investors Menu

  • Overview
  • Press Releases
  • Events and Presentations
    • Event Calendar
    • Presentations
  • Stock Information
    • Stock Chart & Quote
    • Historic Price Lookup
    • Analyst Coverage
    • Investment Calculator
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Financial information
    • SEC Filings
    • Annual reports and proxy materials
  • Investor FAQs
  • Email Alerts
  • Contact IR
  • IR Search

Presentations

Presentations

May 16, 2022
May 2022 Corporate Presentation
October 21, 2021
ESGCT 2021 - Process development
October 21, 2021
ESGCT 2021 - Selective advantage (MMA, Wilson, Tyrosinemia)
October 21, 2021
ESGCT 2021 - Analytical development
October 20, 2021
ESGCT 2021 – Tyrosinemia
May 14, 2021
2021 ASGCT Annual Meeting – Methylmalonic Acidemia
May 14, 2021
2021 ASGCT Annual Meeting – Crigler-Najjar
May 11, 2021
2021 ASGCT Annual Meeting – sAAVy sL65
May 3, 2021
2021 ACMG Annual Meeting - Methylmalonic Acidemia
May 12, 2020
2020 ASGCT Annual Meeting – CMC Potency

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
© 2022 LogicBio Therapeutics, Inc.
  • Privacy Policy
  • Contact